

1654

## AMENDMENT TRANSMITTAL LETTER (Small Entity)

Applicant(s): James H. Aylward

Docket No.

14923A

Serial No.  
09/888,178Filing Date  
June 21, 2001  
O I PExaminer  
C. TateGroup Art Unit  
1654

Invention:

ANTI-CANCER COMPOUNDS



TO THE ASSISTANT COMMISSIONER FOR PATENTS:

RECEIVED  
JAN 07 2003  
TECH CENTER 1600  
U.S. PATENT & TRADEMARK OFFICE

Transmitted herewith is an amendment in the above-identified application.

Small Entity status of this application has been established under 37 CFR 1.27 by a verified statement previously submitted.

A verified statement to establish Small Entity status under 37 FR 1.27 is enclosed.

The fee has been calculated and is transmitted as shown below.

## CLAIMS AS AMENDED

	CLAIMS REMAINING AFTER AMENDMENT	HIGHEST # PREV. PAID FOR	NUMBER EXTRA CLAIMS PRESENT	RATE	ADDITIONAL FEE
TOTAL CLAIMS	63 -	63 =	0	x \$9.00	\$0.00
INDEP. CLAIMS	3 -	3 =	0	x \$42.00	\$0.00
Multiple Dependent Claims (check if applicable)		<input type="checkbox"/>			\$0.00
					TOTAL ADDITIONAL FEE FOR THIS AMENDMENT
					\$0.00

No additional fee is required for amendment.

Please charge Deposit Account No. in the amount of  
A duplicate copy of this sheet is enclosed.

A check in the amount of to cover the filing fee is enclosed.

The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 19-1013/SSMP  
A duplicate copy of this sheet is enclosed.

Any additional filing fees required under 37 C.F.R. 1.16.

Any patent application processing fees under 37 CFR 1.17.

Signature

Dated: January 3, 2003

Mark J. Cohen  
Registration No. 32,211  
Scully, Scott, Murphy & Presser  
400 Garden City Plaza  
Garden City, NY 11530  
(516) 742-4343

I certify that this document and fee is being deposited on 1/3/03 with the U.S. Postal Service as first class mail under 37 C.F.R. 1.8 and is addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Signature of Person Mailing Correspondence

Mishelle Mustafa

Typed or Printed Name of Person Mailing Correspondence

cc:



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

PATENTS

**Applicant(s):** James H. Aylward

**Examiner:** C. Tate

**Serial No:** 09/888,997

**Art Unit:** 1654

**Filed:** June 21, 2001

**Docket:** 14923A

**For:** METHOD OF STIMULATING THE  
IMMUNE SYSTEM

**Dated:** January 3, 2003

Assistant Commissioner for Patents  
Washington, D.C. 20231

**RECEIVED**  
#8  
JAN 07 2003  
TECH CENTER 1600/2900

Sir:

**RESPONSE**

In response to the Restriction Requirement dated December 3, 2003, and in accordance with the provisions of 37 C.F.R. §§1.111 and 1.143, applicant provisionally elects the subject matter of Group I, i.e., Claims 33-77 and 82-92, for continued examination herein.

**REMARKS**

Claims 33-95 are pending in the above-identified application and have been subjected to a Restriction Requirement under 35 U.S.C. §121 as follows:


“I. Claims 33-77 and 82-92, drawn to a method of simulating the immune system using a singular compound, classified in class 514, subclass 100+.

---

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on **January 3, 2003**.

Dated: January 3, 2003



Mishelle Mustafa